{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:46:37Z","timestamp":1793735197925,"version":"4.6.1"},"reference-count":102,"publisher":"American Society of Hematology","issue":"12","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venetoclax (VEN) received full approval in October 2020 for use in older patients who are unfit with acute myeloid leukemia (AML) combined with either hypomethylating agents or low-dose cytarabine. This ended a semicentennial of stalled clinical progress and initiated a new treatment option with proven capacity to enhance response and prolong survival in older patients with AML. Despite widespread use of azacitidine-VEN (AZA-VEN), there is increasing appreciation that this regimen is myelosuppressive and associated with a higher risk of infectious complications than AZA alone. Key principles of initial management include prevention of tumor lysis syndrome in patients at high risk and minimizing infectious complications during induction. In the postremission phase, limiting cumulative marrow suppression by allowing sufficient time between cycles for optimal marrow recovery and truncating the duration of VEN exposure for those with delayed blood count recovery have emerged as important axioms of effective care. This article casts a clinical spotlight on important challenges and dilemmas encountered in practice. We also outline a structured framework to assist in the safe management of AZA-VEN in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024009","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:03:15Z","timestamp":1727190195000},"page":"1237-1250","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["How I treat patients with AML using azacitidine and venetoclax"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-2691","authenticated-orcid":false,"given":"Sun","family":"Loo","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Australia"},{"name":"3Department of Haematology, Northern Hospital, Epping, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"4Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2025032015213085100_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025032015213085100_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"2025032015213085100_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Apoptosis: ABT737 kills more efficiently if Mcl-1 is neutralised","volume":"10","author":"Van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"2","key":"2025032015213085100_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"issue":"10","key":"2025032015213085100_bib5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2025032015213085100_bib6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"2025032015213085100_bib7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2025032015213085100_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2025032015213085100_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025032015213085100_bib10","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood-2019-127423","article-title":"Management of neutropenia during venetoclax-based combination treatment in patients with newly diagnosed acute myeloid leukemia [abstract]","volume":"134","author":"Pratz","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2025032015213085100_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2025032015213085100_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"24","key":"2025032015213085100_bib13","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations\u00a0treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025032015213085100_bib25","doi-asserted-by":"crossref","first-page":"106844","DOI":"10.1016\/j.leukres.2022.106844","article-title":"Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia","volume":"117","author":"Arora","year":"2022","journal-title":"Leuk Res"},{"issue":"3","key":"2025032015213085100_bib102","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine\u00a0or low-dose cytarabine in the UK\u00a0NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"20","key":"2025032015213085100_bib14","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2025032015213085100_bib15","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"issue":"7","key":"2025032015213085100_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"Apel","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"2025032015213085100_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis","volume":"12","author":"Kwag","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025032015213085100_bib18","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"key":"2025032015213085100_bib19","doi-asserted-by":"crossref","first-page":"106803","DOI":"10.1016\/j.leukres.2022.106803","article-title":"Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience","volume":"114","author":"De Bellis","year":"2022","journal-title":"Leuk Res"},{"issue":"11","key":"2025032015213085100_bib20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"Oncol"},{"issue":"5","key":"2025032015213085100_bib21","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","article-title":"Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting","volume":"23","author":"Gershon","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2025032015213085100_bib22","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.34608","article-title":"AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia","volume":"129","author":"Todisco","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"2025032015213085100_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"issue":"S3","key":"2025032015213085100_bib24","doi-asserted-by":"crossref","first-page":"e4811210","DOI":"10.1097\/01.HS9.0000969188.48112.10","article-title":"Outpatient initiation of venetoclax-azacitidine for selected acute myeloid leukemia patients is feasible and save: a real world single center analysis","volume":"7","author":"Gat","year":"2023","journal-title":"Hemasphere"},{"issue":"4","key":"2025032015213085100_bib26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"2025032015213085100_bib27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2014.90","article-title":"The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial","volume":"28","author":"Lazenby","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2025032015213085100_bib28","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"2025032015213085100_bib29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","author":"D\u00f6hner","year":"12  2024","journal-title":"Blood"},{"key":"2025032015213085100_bib30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","author":"D\u00f6hner","year":"12  2024","journal-title":"Blood"},{"key":"2025032015213085100_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.HS9.0000844928.23775.aa","article-title":"P510: the impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia","volume":"6","author":"DiNardo","year":"2022","journal-title":"HemaSphere"},{"issue":"7","key":"2025032015213085100_bib32","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1177\/10781552221142872","article-title":"Outpatient initiation of venetoclax in patients with acute myeloid leukemia","volume":"29","author":"Palmer","year":"2023","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"3","key":"2025032015213085100_bib33","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.1002\/ajh.26060","article-title":"Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax","volume":"96","author":"Diao","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"2025032015213085100_bib34","doi-asserted-by":"crossref","first-page":"ofac486","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Inf Dis"},{"issue":"1","key":"2025032015213085100_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"2025032015213085100_bib36","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025032015213085100_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"key":"2025032015213085100_bib38","first-page":"1","article-title":"Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections","volume":"8","author":"Wiederhold","year":"2016","journal-title":"Clin Pharmacol"},{"issue":"6","key":"2025032015213085100_bib39","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/pharmaceutics15061680","article-title":"Pharmacokinetics of venetoclax co-administered with posaconazole in patients with acute myeloid leukemia","volume":"15","author":"De Gregori","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"2025032015213085100_bib40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025032015213085100_bib41","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3324\/haematol.2023.282681","article-title":"Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia","volume":"108","author":"Gutman","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025032015213085100_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2023-185437","article-title":"Acute myeloid leukemia patients who stopped venetoclax or\/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival. a Filo study [abstract]","volume":"142","author":"Garciaz","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025032015213085100_bib43","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025032015213085100_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.26395","article-title":"Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy","volume":"97","author":"Sasaki","year":"2022","journal-title":"Am J Hematol"},{"issue":"33","key":"2025032015213085100_bib45","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025032015213085100_bib46","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","article-title":"Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A","volume":"97","author":"Pratz","year":"2022","journal-title":"Am J Hematol"},{"issue":"13","key":"2025032015213085100_bib52","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025032015213085100_bib57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/labmed\/lmz094","article-title":"Monocytic maturation induced by FLT3 inhibitor therapy of acute myeloid leukemia: morphologic and immunophenotypic characteristics","volume":"51","author":"Arries","year":"2020","journal-title":"Lab Med"},{"issue":"10","key":"2025032015213085100_bib77","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"2025032015213085100_bib78","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025032015213085100_bib79","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025032015213085100_bib80","doi-asserted-by":"crossref","first-page":"106317","DOI":"10.1016\/j.leukres.2020.106317","article-title":"Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study","volume":"91","author":"Lou","year":"2020","journal-title":"Leuk Res"},{"issue":"8","key":"2025032015213085100_bib81","first-page":"1684","article-title":"Venetoclax-based regimens for relapsed\/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience","volume":"10","author":"Piccini","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"2025032015213085100_bib82","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1097\/HS9.0000000000000549","article-title":"Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies","volume":"5","author":"Feld","year":"2021","journal-title":"Hemasphere"},{"issue":"3","key":"2025032015213085100_bib83","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"2025032015213085100_bib84","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"2025032015213085100_bib85","doi-asserted-by":"crossref","first-page":"649209","DOI":"10.3389\/fonc.2021.649209","article-title":"Outcomes of adults with relapsed\/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center","volume":"11","author":"Tenold","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"2025032015213085100_bib47","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2025032015213085100_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032015213085100_bib49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41408-023-00948-x","article-title":"Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study","volume":"13","author":"Wang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025032015213085100_bib50","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1002\/ajh.26057","article-title":"Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia","volume":"96","author":"Arslan","year":"2021","journal-title":"Am J Hematol"},{"issue":"13","key":"2025032015213085100_bib51","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-naive patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025032015213085100_bib53","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"2025032015213085100_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025032015213085100_bib55","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","article-title":"Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax","volume":"5","author":"Lachowiez","year":"2021","journal-title":"Blood Adv"},{"issue":"19","key":"2025032015213085100_bib56","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025032015213085100_bib58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10388","key":"2025032015213085100_bib59","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"17","key":"2025032015213085100_bib60","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"35","key":"2025032015213085100_bib61","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2025032015213085100_bib62","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-20-3114","article-title":"Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia","volume":"27","author":"Dumas","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2025032015213085100_bib63","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025032015213085100_bib64","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"2025032015213085100_bib65","doi-asserted-by":"crossref","first-page":"e68978fe","DOI":"10.1097\/01.HS9.0000969008.68978.fe","article-title":"Long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax\u00a0+ HMA therapies","volume":"7","author":"Pratz","year":"2023","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2025032015213085100_bib66","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1182\/blood-2023-178008","article-title":"Treatment outcomes of stem cell transplant in patients with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents: experience from\u00a0routine clinical practices in the United States [abstract]","volume":"142","author":"Bachiashvili","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025032015213085100_bib67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025032015213085100_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","article-title":"Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia","volume":"16","author":"Bahaj","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"2025032015213085100_bib69","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.jtct.2023.03.008","article-title":"TP53 mutations are associated with increased infections and reduced hematopoietic cell transplantation rates in myelodysplastic syndrome and acute myeloid leukemia","volume":"29","author":"Marvin-Peek","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"2025032015213085100_bib70","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025032015213085100_bib71","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2022-163841","article-title":"Prolonged survival in bi-allelic TP53-mutated (TP53mut) MDS subjects treated with oral decitabine\/cedazuridine in the Ascertain trial (ASTX727-02) [abstract]","volume":"140","author":"Savona","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025032015213085100_bib72","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"issue":"22","key":"2025032015213085100_bib73","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2025032015213085100_bib74","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023020855","article-title":"TP53 status and impact on AML prognosis within the ELN 2022 risk classification","volume":"142","author":"Fleming","year":"2023","journal-title":"Blood"},{"issue":"15","key":"2025032015213085100_bib75","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025032015213085100_bib76","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2025032015213085100_bib86","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2025032015213085100_bib87","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1182\/blood-2022-167097","article-title":"Venetoclax-based non-intensive combinations successfully salvage molecular relapse of acute myeloid leukemia and are an important bridge to cellular therapy in relapsed\/refractory disease \u2013 real-world data from a UK-wide programme [abstract]","volume":"140","author":"Wood","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2025032015213085100_bib88","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"2025032015213085100_bib89","doi-asserted-by":"crossref","first-page":"841276","DOI":"10.3389\/fonc.2022.841276","article-title":"Combination of venetoclax and midostaurin efficiently suppressed relapsed t(8;21)acute myeloid leukemia with mutant KIT after failure of venetoclax plus azacitidine treatment","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"2025032015213085100_bib90","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"13","key":"2025032015213085100_bib91","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanmaki","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025032015213085100_bib92","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2025032015213085100_bib93","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025032015213085100_bib94","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"2025032015213085100_bib95","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"20","key":"2025032015213085100_bib96","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"issue":"suppl 7","key":"2025032015213085100_bib97","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1538-7445.AM2023-2530","article-title":"DELE1 loss and dysfunctional integrated stress signaling in TP53 mutated AML is a novel pathway for venetoclax resistance","volume":"83","author":"Sharon","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2025032015213085100_bib98","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood-2019-127182","article-title":"TP73 as novel determinant of resistance to BCL-2 inhibition in acute myeloid leukemia [abstract]","volume":"134","author":"Nishida","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025032015213085100_bib99","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2025032015213085100_bib100","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"12","key":"2025032015213085100_bib101","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem\u00a0cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/12\/1237\/2359133\/blood_bld-2024-024009-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/12\/1237\/2359133\/blood_bld-2024-024009-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:51:22Z","timestamp":1742493082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/12\/1237\/517960\/How-I-treat-patients-with-AML-using-azacitidine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,3,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024009","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}